Wells Fargo lowered the firm’s price target on Concentra (CON) to $25 from $27 and keeps an Overweight rating on the shares. The firm is also updating its estimates to reflect Q4 results and Physicians Health Center deal. Out-year EBITDA estimates slightly raised, with core EBITDA growth better than previously modeled in 2025, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra Group Holdings: Strategic Acquisitions Bolster Growth and Justify Buy Rating
- Concentra price target raised to $26 from $24 at Goldman Sachs
- Concentra upgraded to Hold from Sell at Spin-Off Research
- Concentra price target raised to $26 from $25 at BofA
- Positive Outlook for Concentra Group Holdings: Buy Rating Reinforced by Strong Q4 Results and Strategic Acquisitions